Mylan Laboratories Limited (FDF-2) FDA Record
- Latest inspection OAI · Aug 25, 2026
- No warning letters matched by name
Mylan Laboratories Limited (FDF-2) has 0 FDA recalls, 7 inspections, 0 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "Mylan Laboratories Limited (FDF-2)" is on file.
- Latest inspection
- Aug 25, 2026 · OAI
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 0 | Nov 15, 2026 | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 0 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 7 | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Compliance actions | 0 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
Mylan Laboratories Limited (FDF-2): FDA inspections per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 1 | 1 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 1 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 1 | 0 | 0 | 0 | 0 |
| 2019 | 1 | 0 | 0 | 0 | 0 |
| 2018 | 0 | 0 | 0 | 0 | 0 |
| 2017 | 1 | 0 | 0 | 0 | 0 |
Reviewing Mylan Laboratories Limited (FDF-2) as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Mylan Laboratories Limited (FDF-2) yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Recent FDA inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| Aug 25, 2026 | Chhatrapati Sambhajinagar, India | Drugs | Official Action Indicated (OAI) | 3008316970 |
| Feb 3, 2023 | Chhatrapati Sambhajinagar, India | Drugs | Voluntary Action Indicated (VAI) | 3008316970 |
| Feb 28, 2020 | Chhatrapati Sambhajinagar, India | Drugs | No Action Indicated (NAI) | 3008316970 |
| Apr 26, 2019 | Chhatrapati Sambhajinagar, India | Drugs | No Action Indicated (NAI) | 3008316970 |
| May 26, 2017 | Chhatrapati Sambhajinagar, India | Drugs | Voluntary Action Indicated (VAI) | 3008316970 |
| May 16, 2014 | Chhatrapati Sambhajinagar, India | Drugs | No Action Indicated (NAI) | 3008316970 |
| Mar 9, 2012 | Chhatrapati Sambhajinagar, India | Drugs | Voluntary Action Indicated (VAI) | 3008316970 |
- NAI
- No objectionable conditions or practices were found during the inspection.
- VAI
- Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
- OAI
- Regulatory and/or administrative actions are recommended.
FDA-inspected facilities
| Facility | Location | Inspections | Latest |
|---|---|---|---|
| FEI 3008316970 | Chhatrapati Sambhajinagar, India | 7 | Aug 25, 2026 |
Mylan Laboratories Limited (FDF-2) and the FDA: common questions
Has Mylan Laboratories Limited (FDF-2) received an FDA warning letter?
No FDA warning letter addressed to the name "Mylan Laboratories Limited (FDF-2)" is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.
Has Mylan Laboratories Limited (FDF-2) received an FDA Form 483?
FDA has not published a Form 483 for "Mylan Laboratories Limited (FDF-2)" in its reading room. FDA publishes some Form 483s, not all of them.
When did the FDA last inspect Mylan Laboratories Limited (FDF-2)?
The most recent FDA inspection on file ended Aug 25, 2026 at Chhatrapati Sambhajinagar, India and was classified OAI. FDA has 7 inspections of Mylan Laboratories Limited (FDF-2) on file, 1 of them classified OAI (official action indicated).
Need more than this page shows? Ask about Mylan Laboratories Limited (FDF-2) in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.